Non-neoplastic liver diseases remodel endocrine, metabolic, and stromal circuits in ways that plausibly alter IGFBP-6 production, processing, and release into blood, but direct evidence is uneven across etiologies and often stage-dependent, necessitating disease-specific appraisal and careful interpretation of serum versus intrahepatic signals (Table 2). Here, IGFBP6 is linked to liver disorder.